Spruce Biosciences, Inc. (SPRB) PT Lowered to $1.50 at RBC Capital Following Study Fail
Tweet Send to a Friend
RBC Capital analyst Gregory Renza lowered the price target on Spruce Biosciences, Inc. (NASDAQ: SPRB) to $1.50 (from $2.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
